No / Dystroglycan is frequently lost in adenocarcinoma, but the mechanisms and consequences are poorly understood. We report an analysis of beta-dystroglycan in prostate cancer in human tissue samples and in LNCaP cells in vitro. There is progressive loss of beta-dystroglycan immunoreactivity from basal and lateral surfaces of prostate epithelia which correlates significantly with increasing Gleason grade. In about half of matched bone metastases there is significant dystroglycan re-expression. In tumour tissue and in LNCaP cells there is also a tyrosine phosphorylation-dependent translocation of beta-dystroglycan to the nucleus. Analysis of gene expression data by microarray, reveals that nuclear targeting of beta-dystroglycan in LNCaP cells alters the transcription of relatively few genes, the most unregulated being the transcription factor ETV1. These data suggest that proteolysis, tyrosine phosphorylation and translocation of dystroglycan to the nucleus resulting in altered gene transcription could be important mechanisms in the progression of prostate cancer.
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/9555 |
| Date | January 2013 |
| Creators | Mathew, G., Mitchell, Andrew, Down, J.M., Jacobs, L.A., Hamdy, F.C., Eaton, C., Rosario, D.J., Cross, S.S., Winder, S.J. |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Article, No full-text in the repository |
Page generated in 0.0026 seconds